AbstractBySubCategory

HER2+

Breast Cancer—HER2/ER

2015 ASCO Annual Meeting

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P). Luca Gianni

505

Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial. Nadia Harbeck

506

Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET). Arlene Chan

508

Meta-analysis of breast cancer expression data using published gene signatures to reveal key cellular processes implicated in chemosensitivity and resistance. Daniel G. Stover

509

Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer. Minoru Miyashita

510

Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials. Sibylle Loibl

511

Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3. Dennis J. Slamon

512

Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors. Howard A. Burris

523

Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial. Debu Tripathy

524

Docetaxel, cyclophosphamide and trastuzumab as neoadjuvant chemotherapy in HER2-positive primary breast cancer. Katsuhiko Nakatsukasa

583

Phase I study of HER3 targeted antibody patritumab in combination with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC). Toshiaki Saeki

584

Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC). Christian Jackisch

585

The co-administration of pertuzumab (P) and trastuzumab (T) as a single infusion, followed by vinorelbine (V), in first-line (1L) treatment of HER2-positive locally advanced or metastatic breast cancer (MBC) patients (pts): VELVET study interim analysis. Michael Andersson

586

Associations of HER2-specific immunity with survival during treatment with trastuzumab and chemotherapy in breast cancer. Keith L. Knutson

587

Neoadjuvant chemotherapy in the real world: A study of 22,819 patients from the Japanese National Clinical Database-Breast Cancer Registry. Naoki Niikura

588

Graded prognostic assessment (GPA) of HER2 positive breast cancer patients with brain metastases. Ming Chi

589

Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC). Payal Deepak Shah

590

Effectiveness of targeting HER2 in heavily pretreated patients with occult HER2-positive (tissue-negative, serum-positive and/or HER2-positive circulating tumor cells) metastatic breast cancer in the clinical routine. Christian M. Kurbacher

591

Implications of high tumor infiltrating lymphocytes (TIL) in HER2-positive and triple-negative breast cancer (TNBC). Vassiliki Kotoula

592

Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer. Beatrice Bachmeier

593

Prognostic impact of HER2 overexpression/amplification in women with pT1a N0 M0 breast cancer with known screening status: First results from a multicenter population-based cancer registry study. Antonino Musolino

594

Evaluation of the Breast Cancer Index in patients with HER2+/HR+ breast cancer for risk of late recurrence and potential extended endocrine benefit. Ruth O'Regan

595

Determining whether functional subtyping with BluePrint 80-gene profile could potentially identify two distinct triple positive subtypes with and without trastuzumab/chemo-sensitivity. Pat W. Whitworth

596

Effect of ranolazine administered after trastuzumab treatment on cardiotoxicity in mice. Nicola Maurea

597

Skin and subcutaneous tissue disorders (SSTDs) in patients (pts) with HER2-positive metastatic breast cancer (MBC) in the phase III trial CLEOPATRA of pertuzumab or placebo with trastuzumab and docetaxel. David Miles

598

Biologic characteristics of breast cancer in male compared to female: SEER analysis. Mohammed Shaik

599

Effect of high MMP2 and low MMP9 baseline serum levels on outcome in patients with HER2-positive inflammatory breast cancer (IBC) treated with bevacizumab (BEV)- and trastuzumab (TRA)-based neoadjuvant chemotherapy (NAC) in the BEVERLY 2 study. Emeline Tabouret

600

Expression levels of PARP1 and phospho-p65 protein in human HER2-positive breast cancers. Jennifer Anne Stanley

601

Phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line + treatment of HER2+ metastatic breast cancer (MBC). Erika Paige Hamilton

602

Safety of trastuzumab emtansine (T-DM1) in 373 patients 65 years or older with HER2-positive advanced breast cancer: A subgroup analysis of the Kamilla study. Carlos H. Barrios

603

The clinical utility of ERBB2 amplification detection in breast carcinoma using a 341 gene hybrid capture-based next generation sequencing (NGS) assay: Comparison with standard immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) assays. Dara S. Ross

604

HER2 quantification by mass spectrometry compared to IHC or ISH in predicting clinical benefit from anti-HER2 therapy in HER2-positive breast cancer (BC). Paolo Nuciforo

605

Crosstalk between PARP-1 and NF-κB signaling pathways as a potential determinant of PARPi sensitivity in trastuzumab resistant HER2+ breast cancer cell lines. Monicka Wielgos

606

Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result. Lillian Mary Smyth

607

A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with HER2+ metastatic breast cancer (MBC). Komal L. Jhaveri

608

Characterization of dominant T-cell clones by T-cell receptor (TCR) deep sequencing as a potential predictive biomarker to neoadjuvant trastuzumab (tras) in HER2-positive (HER2+) breast cancer. David B. Page

609

Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT). Ahmad Awada

610

Whole exome sequencing (WES) in HER2+ metastatic breast cancer (MBC) patients (pts) with extraordinary responses to trastuzumab (T). Ines Maria Vaz Duarte Luis

611

ONT-380 in the treatment of HER2+ breast cancer central nervous system (CNS) metastases (mets). Cristiano Ferrario

612

Lack of correlation of neoantigens arising from tumor somatic mutations with tumor infiltrating lymphocytes (TILs) or survival in HER2-positive breast cancer (HER2+ BC). Peter Stephen Savas

613

Neuromedin U to increase IL-6 levels and to expand cancer stem cells in HER2-positive breast cancer cells. Vanesa Gabriela Martinez

614

Effect of somatic mutations in the four genes of the HER family on occurrence in HER2-positive breast cancer, cell proliferation rates, and resistance to HER2-targeted therapies in vitro. Naomi Elster

615

Trastuzumab and pertuzumab-based versus other therapy as second-line therapy in HER2-positive metastatic breast cancer: A retrospective study from single center. Daniel Fontes Santos De Teive E Argolo

616

HLA-DRB1*07:01 biomarker characterization of hepatotoxicity during lapatinib combination therapies in ALTTO. Colin F. Spraggs

617

Development of PF-05280014, a potential biosimilar to trastuzumab. Ira A Jacobs

618

Association of tumor infiltrating lymphocytes (TILs) with pathologic response in baseline and post-brief exposure HER2+ breast cancer biopsies from BrUOG-211B. Stefanie Avril

619

Mechanisms of acquired afatinib resistance in HER2-positive breast cancer cells. Alexandra Canonici

620

HER3, PI3K, and JAK2 pathway activation on reverse phase protein microarray (RPMA) in HER2-amplified residual disease (RD) refractory to preoperative chemotherapy plus trastuzumab (H), lapatinib (L), or both (HL). Frankie Ann Holmes

621

Final pre-specified analysis of the phase II trial of the AE37+GM-CSF vaccine in high risk breast cancer patients to prevent recurrence. Julia M. Greene

622

Retrospective analysis of cardiac tolerability of concurrent administration of trastuzumab- and anthracycline-based regimen for breast cancer, to address one-year-term issues in LVEF. Naoki Watanabe

e11590

Effect of trastuzumab on the antiproliferative effects of PI3K inhibitors in HER2+ breast cancer cells with de novo resistance to trastuzumab. Estefania Espin

e11592

The relationship of miR-122-5p with trastuzumab therapy in breast cancer. Sercan Ergün

e11593

Effect of curcumin on lapatinib sensitivity and lapatinib resistance associated EMT and stem-like phenotype in HER2 positive breast cancer. Junjun Liu

e11594

Effects of adjuvant trastuzumab with chemotherapy (ATWC) in T1N0 HER2 positive (HER2+) breast cancer. Yada Kanjanapan

e11595

A phase I study for tolerability, safety, and pharmacokinetics of pyrotinib, a novel irreversible HER2 and EGFR inhibitor, in Chinese patients with HER2+ metastatic breast cancer. Binghe Xu

e11596

Cardiotoxicity with adjuvant trastuzumab + anthracycline: Incidence and risk factors in a cohort of 962 HER2+ breast cancers from 2005-2011. Louis Fehrenbacher

e11599

Nanobody-based PET/CT imaging of HER2 expression in breast carcinoma: Phase I results and potential to assess tumor heterogeneity. Marleen Keyaerts

e11600

Cardiac safety of continuous trastuzumab therapy in breast cancer patients with asymptomatic left ventricular dysfunction. Anthony Francis Yu

e11602

Phase II study on the efficacy and safety of lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu: Positive advanced breast cancer (CECOG LaVie Trial). Christiane Thallinger

e11603

Effect of adjuvant trastuzumab (Tadj) therapy (Tx) for early-stage breast cancer (ESBC) on demographics, survival and likelihood of durable complete response (DCR) of HER2+ metastatic breast cancer (HMBC): A 15-year study. Alessandra Zacchia

e11604

Relationship between levels of HER-2 amplification and pathologic complete response to trastuzumab-based neoadjuvant treatment. Cristina Masini

e11605

Prognostic value of PIK3CA mutations in HER2-positive early stage breast cancer: A French cohort study. Florence Coussy

e11607

Prevalence of hypomagnesemia in patients with HER2–positive breast cancer receiving pertuzumab treatment. Tracy Ann Proverbs-Singh

e11608

Analytical validation of Bond Oracle HER2 IHC system for identifying low to intermediate HER2-expressing breast cancer in NeuVax PRESENT phase III clinical trial. Amit K Jain

e11609

Skin, nail, and staphylococcal infections associated with the addition of pertuzumab to trastuzumab-based chemotherapy. Joanne E. Mortimer

e11610

Low tumor-infiltrating lymphocytes (TILs) to predict and refine risk in patients not achieving a pathological complete response (pCR) in HER2-positive breast cancers. Naoki Hayashi

e11612

Pathologic complete response after neoadjuvant chemotherapy as a real surrogate endpoint of outcome for all breast cancer subtypes? Results of a single institution experience. Paola Fuso

e11613

A novel approach to assess Her2-status of circulating tumour cells (CTCs) using the automated BioMarQ System. Elisabeth Katharina Trapp

e11615

Concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for HER2 determination and correlation with clinical and pathological data. Hector Randhall Callata-Carhuapoma

e11616

Neoadjuvant chemotherapy based on dose-dense epirubicin (E) plus cyclophosphamide (C) followed by docetaxel (D) plus trastuzumab (T), DT plus carboplatin (CBDCA), or DT plus HER2 double blockade in HER2-positive breast cancer patients. Lucia Ceniceros

e11617

Prognostic marker discordance between breast and axilla in patients with early breast cancer. Courtney Porter

e11618

HER2 testing in breast cancer by quantitative PCR: technical and clinical considerations. Rong Yu

e11619

Brain Metastases in Breast Cancer Network Germany (BMBC; GBG 79): Multicentric, retro- and prospective collection of patient data and biomaterial from patients with brain metastases. Volkmar Mueller

TPS639

A phase 2 single-arm study to assess clinical activity, efficacy and safety of enzalutamide (ENZA) with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer. Maureen E. Trudeau

TPS640

HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician’s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1). Kathy Miller

TPS641

PATRICIA: A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer. Patricia Villagrasa

TPS642